These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 7495095)

  • 1. Hepatitis C and pasteurised factor VIII and IX concentrates.
    Klarmann D; Kreuz W; Auerswald G; Auberger K; Rabenau H; Gürtler L; Roggendorf M
    Thromb Haemost; 1995 Apr; 73(4):736-7. PubMed ID: 7495095
    [No Abstract]   [Full Text] [Related]  

  • 2. Progress in the clinical management of haemophilia.
    Bloom AL
    Thromb Haemost; 1991 Jul; 66(1):166-77. PubMed ID: 1926047
    [No Abstract]   [Full Text] [Related]  

  • 3. Antibody to hepatitis C (anti C 100-3) in French hemophiliacs.
    Maisonneuve P; Laurian Y; Guerois C; Verroust F; Ferrer Le Coeur F; Couroucé AM; Noel L
    Nouv Rev Fr Hematol (1978); 1991; 33(3):263-6. PubMed ID: 1956764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serological evidence that dry heating of clotting factor concentrates prevents transmission of non-A, non-B hepatitis.
    Skidmore SJ; Pasi KJ; Mawson SJ; Williams MD; Hill FG
    J Med Virol; 1990 Jan; 30(1):50-2. PubMed ID: 2106006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of hepatitis B and C seromarkers and abnormal liver function tests among hemophiliacs in Guilan (northern province of Iran).
    Mansour-Ghanaei F; Fallah MS; Shafaghi A; Yousefi-Mashhoor M; Ramezani N; Farzaneh F; Nassiri R
    Med Sci Monit; 2002 Dec; 8(12):CR797-800. PubMed ID: 12503038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis A among persons with hemophilia who received clotting factor concentrate--United States, September-December 1995.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1996 Jan; 45(2):29-32. PubMed ID: 8531917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
    Schimpf K; Schwarz P; Kunschak M
    Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845
    [No Abstract]   [Full Text] [Related]  

  • 8. [Transmission of hepatitis C by factor concentrates].
    Aguilar C; Lucía JF
    Sangre (Barc); 1996 Apr; 41(2):160-1. PubMed ID: 9045360
    [No Abstract]   [Full Text] [Related]  

  • 9. Virus safety of pasteurized factor VIII and factor IX concentrates: study in virgin patients.
    Heimburger N; Karges HE; Weidmann E
    Dev Biol Stand; 1987; 67():303-10. PubMed ID: 3038638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From the Centers for Disease Control and Prevention. Hepatitis A among persons with hemophilia who received clotting factor concentrate--United States, September-December 1995.
    JAMA; 1996 Feb; 275(6):427-8. PubMed ID: 8627951
    [No Abstract]   [Full Text] [Related]  

  • 11. [Teeth extractions in 35 patients with hemophilia].
    Zhou SM; Gi LX; Yang TY
    Zhonghua Kou Qiang Yi Xue Za Zhi; 1994 Sep; 29(5):291-3. PubMed ID: 7743865
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of hemophilia complicated by inhibitors.
    Scand J Haematol Suppl; 1980; 35():135-64. PubMed ID: 6770458
    [No Abstract]   [Full Text] [Related]  

  • 13. Recombinant factor VIII in hemophilia A: the Canadian experience.
    Blanchette VS
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
    Sultan Y; Boyeldieu D; Stieltjes N
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short incubation non-A, non-B hepatitis transmitted by factor VIII concentrates in patients with congenital coagulation disorders: a preliminary report of an antigen/antibody system.
    Bamber M; Murray A; Kernoff PB; Thomas HC
    Med Lab Sci; 1981 Oct; 38(4):373-8. PubMed ID: 6799726
    [No Abstract]   [Full Text] [Related]  

  • 16. [Viral hepatitis in hemophiliac patients treated with commercial concentrates of factors VIII and IX].
    Miranda ML; Lissen E; Vinuesa M; Jiménez JM; García de Pesquera F; Leal M
    Med Clin (Barc); 1985 Apr; 84(13):516-9. PubMed ID: 3923278
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapy-induced hepatitis risk in hemophilia patients].
    Schiller WG; Renger FG
    Z Arztl Fortbild (Jena); 1983; 77(19):807-10. PubMed ID: 6417919
    [No Abstract]   [Full Text] [Related]  

  • 18. [Technic of obtaining the antihemophilic factors VIII and IX and their clinical application].
    Triginer J; Vila M; Vicente Arangüena P
    Sangre (Barc); 1979; 24(5-C):937-41. PubMed ID: 121169
    [No Abstract]   [Full Text] [Related]  

  • 19. Addition of hepatitis-B immunoglobulin to clotting factor.
    Scaroni C; Cancellieri V; Carnelli V; Moroni GA; Angeli M
    Lancet; 1980 Sep; 2(8193):537-8. PubMed ID: 6105587
    [No Abstract]   [Full Text] [Related]  

  • 20. [Improvement in anti-hemophilic preparations and arts problems. 1. Heat-treated concentrates].
    Ikematsu S; Yorifuji H; Arai M; Fukutake K
    Rinsho Ketsueki; 1988 May; 29(5):628-34. PubMed ID: 3145993
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.